View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSolgenics 過去の業績過去 基準チェック /06Solgenics は平均年間 5.2% の収益成長を遂げていますが、Oil and Gas 業界では年間 収益成長率 となっています。10.7% です。主要情報5.20%収益成長率14.20%EPS成長率Oil and Gas 業界の成長37.29%収益成長率n/a株主資本利益率-15.78%ネット・マージンn/a前回の決算情報30 Jun 2022最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • May 04Solgenics Proposes DelistingSolgenics Limited announced that it will shortly be posting a circular to shareholders in connection with a proposal for the cancellation of admission of the ordinary shares of no par value in the Company to trading on AIM, pursuant to Rule 41 of the AIM Rules for Companies. The Directors have conducted a review of the benefits and drawbacks to the Company and its shareholders in retaining its quotation on AIM, and believe that Cancellation is in the best interest of the Company and its shareholders as a whole. In reaching this conclusion, the Directors have considered the following key factors: the continued listing on AIM is unlikely to provide the Company with significantly wider or more cost-effective access to capital than the funding options it already has from majority shareholders in the near to mid-term; with a market capitalisation of £3.26 million the Directors have concluded that the most likely source of future funds will be through private capital; the considerable cost, management time and legal and regulatory burden associated with maintaining the Company's admission to trading on AIM are disproportionate to the benefits to the Company; there are negative operational influences on the business which come about directly as a result of being quoted, something which is accentuated by operating in an industry where the vast majority of the Company's peers are privately owned. The Company's peers also have far greater insight into its strategy, operational activities and future plans than the Company has into theirs, a factor which reduces the Company's relative competitiveness; the Company's market capitalisation and lack of liquidity in the Ordinary Shares have impacted certain of the potential advantages to having the shares admitted to trading on AIM. Accordingly, the Directors believe that it is in the best interests of the Company and its shareholders as a whole to cancel the admission of the Company's Ordinary Shares to trading on AIM. The Board does not consider that any potential benefits to the Company or Shareholders from retaining the AIM Admission are sufficient to justify the associated costs. In accordance with Rule 41 of the AIM Rules, the Company's Nominated Adviser has notified the London Stock Exchange of the proposed Cancellation. Pursuant to AIM Rule 41, the Cancellation can only be effected by the Company after securing a resolution of Shareholders in a general meeting passed by a requisite majority, being not less than 75 per cent. of the votes cast by Shareholders (in person or by proxy). The Directors have indicated they will vote in favour of the Cancellation. Under the AIM Rules, the Cancellation can only take place after the expiry of a period of twenty Business Days from the date on which notice of the Cancellation is given. In addition, a period of at least five Business Days following the Shareholder approval of the Cancellation is required before the Cancellation may be put into effect. Accordingly, if the Resolution to cancel the Admission is approved, the last day of dealings in the Ordinary Shares on AIM is expected to be 6 June 2023, and the Cancellation is expected to become effective at 7.00 a.m. on 7 June 2023.Recent Insider Transactions • Jan 19Non-Executive Director recently bought €63k worth of stockOn the 16th of January, Scott Fletcher bought around 7m shares on-market at roughly €0.0087 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €145k more in shares than they have sold in the last 12 months.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Scott Fletcher was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • May 16Non-Executive Director recently bought €54k worth of stockOn the 9th of May, Scott Fletcher bought around 5m shares on-market at roughly €0.011 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Scott Fletcher was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Apr 09Non-Executive Director recently bought €409k worth of stockOn the 6th of April, Scott Fletcher bought around 10m shares on-market at roughly €0.041 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €9.8m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Nov 20Insider recently bought €9.2m worth of stockOn the 16th of November, Scott Fletcher bought around 2m shares on-market at roughly €4.20 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.収支内訳Solgenics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:9NE 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Jun 220-22031 Mar 220-22031 Dec 210-22030 Jun 210-22031 Mar 210-22031 Dec 200-32030 Sep 200-32030 Jun 200-22031 Mar 200-22031 Dec 190-22030 Sep 190-22030 Jun 190-22031 Mar 190-32031 Dec 180-33030 Sep 180-33030 Jun 180-32031 Mar 180-32031 Dec 170-21030 Sep 170-21030 Jun 170-31031 Mar 170-32031 Dec 160-32030 Sep 160-22030 Jun 160-12031 Mar 160-22031 Dec 150-23030 Sep 150-194030 Jun 150-375031 Mar 150-375031 Dec 140-386030 Sep 140-226030 Jun 140-66031 Mar 140-77031 Dec 130-77030 Sep 130-88030 Jun 130-88031 Mar 130-88031 Dec 120-99030 Sep 120-1090質の高い収益: 9NEは現在利益が出ていません。利益率の向上: 9NEは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 9NEは利益を出していないが、過去 5 年間で年間5.2%の割合で損失を削減してきた。成長の加速: 9NEの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 9NEは利益が出ていないため、過去 1 年間の収益成長をOil and Gas業界 ( -9.2% ) と比較することは困難です。株主資本利益率高いROE: 9NEは現在利益が出ていないため、自己資本利益率 ( -15.78% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YEnergy 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/06/29 17:35終値2023/06/06 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Solgenics Limited これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Alexander BrooksCanaccord GenuityMartin PottsCavendishAndrey LitvinEdison Investment Research
お知らせ • May 04Solgenics Proposes DelistingSolgenics Limited announced that it will shortly be posting a circular to shareholders in connection with a proposal for the cancellation of admission of the ordinary shares of no par value in the Company to trading on AIM, pursuant to Rule 41 of the AIM Rules for Companies. The Directors have conducted a review of the benefits and drawbacks to the Company and its shareholders in retaining its quotation on AIM, and believe that Cancellation is in the best interest of the Company and its shareholders as a whole. In reaching this conclusion, the Directors have considered the following key factors: the continued listing on AIM is unlikely to provide the Company with significantly wider or more cost-effective access to capital than the funding options it already has from majority shareholders in the near to mid-term; with a market capitalisation of £3.26 million the Directors have concluded that the most likely source of future funds will be through private capital; the considerable cost, management time and legal and regulatory burden associated with maintaining the Company's admission to trading on AIM are disproportionate to the benefits to the Company; there are negative operational influences on the business which come about directly as a result of being quoted, something which is accentuated by operating in an industry where the vast majority of the Company's peers are privately owned. The Company's peers also have far greater insight into its strategy, operational activities and future plans than the Company has into theirs, a factor which reduces the Company's relative competitiveness; the Company's market capitalisation and lack of liquidity in the Ordinary Shares have impacted certain of the potential advantages to having the shares admitted to trading on AIM. Accordingly, the Directors believe that it is in the best interests of the Company and its shareholders as a whole to cancel the admission of the Company's Ordinary Shares to trading on AIM. The Board does not consider that any potential benefits to the Company or Shareholders from retaining the AIM Admission are sufficient to justify the associated costs. In accordance with Rule 41 of the AIM Rules, the Company's Nominated Adviser has notified the London Stock Exchange of the proposed Cancellation. Pursuant to AIM Rule 41, the Cancellation can only be effected by the Company after securing a resolution of Shareholders in a general meeting passed by a requisite majority, being not less than 75 per cent. of the votes cast by Shareholders (in person or by proxy). The Directors have indicated they will vote in favour of the Cancellation. Under the AIM Rules, the Cancellation can only take place after the expiry of a period of twenty Business Days from the date on which notice of the Cancellation is given. In addition, a period of at least five Business Days following the Shareholder approval of the Cancellation is required before the Cancellation may be put into effect. Accordingly, if the Resolution to cancel the Admission is approved, the last day of dealings in the Ordinary Shares on AIM is expected to be 6 June 2023, and the Cancellation is expected to become effective at 7.00 a.m. on 7 June 2023.
Recent Insider Transactions • Jan 19Non-Executive Director recently bought €63k worth of stockOn the 16th of January, Scott Fletcher bought around 7m shares on-market at roughly €0.0087 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €145k more in shares than they have sold in the last 12 months.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Scott Fletcher was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • May 16Non-Executive Director recently bought €54k worth of stockOn the 9th of May, Scott Fletcher bought around 5m shares on-market at roughly €0.011 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Scott Fletcher was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Apr 09Non-Executive Director recently bought €409k worth of stockOn the 6th of April, Scott Fletcher bought around 10m shares on-market at roughly €0.041 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €9.8m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Nov 20Insider recently bought €9.2m worth of stockOn the 16th of November, Scott Fletcher bought around 2m shares on-market at roughly €4.20 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.